{
    "clinical_study": {
        "@rank": "156215", 
        "arm_group": [
            {
                "arm_group_label": "Botulinum toxin type A Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "Botulinum toxin type A Dose 1  intramuscular injections into specified muscles."
            }, 
            {
                "arm_group_label": "Botulinum toxin type A Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "Botulinum toxin type A Dose 2 intramuscular injections into specified muscles."
            }, 
            {
                "arm_group_label": "Placebo (Normal Saline)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo (Normal Saline) intramuscular injections into specified muscles."
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the efficacy and safety of Botulinum Toxin Type A versus placebo (normal saline)\n      as headache prophylaxis in adolescents (children 12 to 17) with chronic migraine."
        }, 
        "brief_title": "A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Migraine Disorders", 
        "condition_browse": {
            "mesh_term": "Migraine Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Medical history of chronic migraine for at least 6 months\n\n          -  15 or more headache days during a 4 week period\n\n        Exclusion Criteria:\n\n          -  Previous use of any botulinum toxin of any serotype for any reason\n\n          -  Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis\n\n          -  Treatment of headache using acupuncture, transcutaneous electrical stimulation\n             (TENS), cranial traction, dental splints, or injection of anesthetics/steroids within\n             4 weeks prior to the week -4 screening visit\n\n          -  Use of any headache prophylaxis medication within 4 weeks prior to the week -4\n             screening visit"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "126", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01662492", 
            "org_study_id": "191622-103"
        }, 
        "intervention": [
            {
                "arm_group_label": "Botulinum toxin type A Dose 1", 
                "description": "Botulinum toxin type A Dose 1 intramuscular injections into specified muscles.", 
                "intervention_name": "Botulinum toxin type A Dose 1", 
                "intervention_type": "Biological", 
                "other_name": [
                    "onabotulinumtoxinA", 
                    "BOTOX\u00ae"
                ]
            }, 
            {
                "arm_group_label": "Botulinum toxin type A Dose 2", 
                "description": "Botulinum toxin type A Dose 2 intramuscular injections into specified muscles.", 
                "intervention_name": "Botulinum toxin type A Dose 2", 
                "intervention_type": "Biological", 
                "other_name": [
                    "onabotulinumtoxinA", 
                    "BOTOX\u00ae"
                ]
            }, 
            {
                "arm_group_label": "Placebo (Normal Saline)", 
                "description": "Placebo (Normal Saline) intramuscular injections into specified muscles.", 
                "intervention_name": "Placebo (Normal Saline)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 9, 2014", 
        "link": {
            "description": "More Information", 
            "url": "http://www.allerganclinicaltrials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Oceanside", 
                    "country": "United States", 
                    "state": "California"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in the frequency of headache days", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 12 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01662492"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in the frequency of severe headache days", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 Weeks"
            }, 
            {
                "measure": "Change from baseline in the total cumulative hours of headache on headache days", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 Weeks"
            }, 
            {
                "measure": "Percentage of patients with \u2265 50% decrease from baseline in the frequency of headache days", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 Weeks"
            }, 
            {
                "measure": "Percentage of patients who are prescribed oral rescue migraine prophylactic treatment", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}